Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/102197
Citations
Scopus Web of Science® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorJuul, R.-
dc.contributor.authorFoster, D.-
dc.contributor.authorUpton, R.-
dc.contributor.authorAndresen, T.-
dc.contributor.authorGraversen, C.-
dc.contributor.authorDrewes, A.-
dc.contributor.authorChristrup, L.-
dc.contributor.authorKreilgaard, M.-
dc.date.issued2014-
dc.identifier.citationBasic and Clinical Pharmacology and Toxicology, 2014; 115(4):343-351-
dc.identifier.issn1742-7835-
dc.identifier.issn1742-7843-
dc.identifier.urihttp://hdl.handle.net/2440/102197-
dc.description.abstractThe purpose of the study was to investigate placebo and buprenorphine effects on event-related potentials (ERPs) in experimental pain and the potential benefit of population pharmacodynamic modelling in data analysis. Nineteen healthy volun- teers received transdermal placebo and buprenorphine in a cross-over study. Drug plasma concentrations and ERPs after electrical stimulation at the median nerve with intensity adjusted to pain detection threshold were recorded until 144 hrs after administra- tion. Placebo and concentration-effect models were fitted to data using non-linear mixed-effects modelling implemented in NON- MEM (V7.2.0.). Pharmacodynamic models were developed to adequately describe both placebo and buprenorphine ERP data. Models predicted significant placebo effects, but did not predict significant effects related to buprenorphine concentration. Mod- els revealed that ERPs varied both between subjects and between study occasions. ERPs were found to be reproducible within subjects and occasions as population variance was found to be eight times higher than the unexplained variances. Between-sub- ject variance accounted for more than 75% of the population variance. In conclusion, pharmacodynamic modelling was success- fully implemented to allow for placebo and variability correction in ERP of experimental pain. Improved outcome of ERP studies can be expected if variation between subjects and-
dc.description.statementofresponsibilityR.V. Juul, D.J.R. Foster, R.N. Upton, T. Andresen, C. Graversen, A.M. Drewes, L.L. Christrup and M. Kreilgaard-
dc.language.isoen-
dc.publisherWiley-
dc.rights© 2014 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society)-
dc.source.urihttp://dx.doi.org/10.1111/bcpt.12217-
dc.subjectHumans-
dc.subjectPain-
dc.subjectBuprenorphine-
dc.subjectAdministration, Cutaneous-
dc.subjectCross-Over Studies-
dc.subjectPain Threshold-
dc.subjectEvoked Potentials-
dc.subjectModels, Theoretical-
dc.subjectMale-
dc.subjectHealthy Volunteers-
dc.titlePharmacodynamic modelling of placebo and buprenorphine effects on event-related potentials in experimental pain-
dc.typeJournal article-
dc.identifier.doi10.1111/bcpt.12217-
pubs.publication-statusPublished-
dc.identifier.orcidFoster, D. [0000-0002-7345-4084]-
dc.identifier.orcidUpton, R. [0000-0001-9996-4886]-
Appears in Collections:Aurora harvest 3
Medical Sciences publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.